# Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants

> **NCT07039929** · PHASE1 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 24 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** INCB000631
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07039929
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-07-28
- **Primary completion:** 2025-10-11
- **Final completion:** 2025-10-11
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Strategic Business Decision
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07039929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07039929, "Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07039929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*